CA2345378A1 - Neuro-immunophillines pour radioprotection neuronale selective - Google Patents

Neuro-immunophillines pour radioprotection neuronale selective Download PDF

Info

Publication number
CA2345378A1
CA2345378A1 CA002345378A CA2345378A CA2345378A1 CA 2345378 A1 CA2345378 A1 CA 2345378A1 CA 002345378 A CA002345378 A CA 002345378A CA 2345378 A CA2345378 A CA 2345378A CA 2345378 A1 CA2345378 A1 CA 2345378A1
Authority
CA
Canada
Prior art keywords
neuroimmunophilin
radiation
ionizing radiation
neurons
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002345378A
Other languages
English (en)
Inventor
Marcus Keep
Eskil Elmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2345378A1 publication Critical patent/CA2345378A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne un procédé et des produits pharmaceutiques permettant de protéger sélectivement les neurones contre les dégâts provoqués par le rayonnement ionisant, indépendamment de la source d'irradiation. Ce procédé est particulièrement utile pour protéger sélectivement les neurones normaux, mais non les cellules cérébrales tumorales, contre les effets dommageables du rayonnement ionisant.
CA002345378A 1998-09-23 1998-09-23 Neuro-immunophillines pour radioprotection neuronale selective Abandoned CA2345378A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1998/020040 WO2000016794A1 (fr) 1998-09-23 1998-09-23 Neuro-immunophillines pour radioprotection neuronale selective

Publications (1)

Publication Number Publication Date
CA2345378A1 true CA2345378A1 (fr) 2000-03-30

Family

ID=22267931

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002345378A Abandoned CA2345378A1 (fr) 1998-09-23 1998-09-23 Neuro-immunophillines pour radioprotection neuronale selective

Country Status (10)

Country Link
EP (1) EP1115412A4 (fr)
JP (1) JP2002526453A (fr)
CN (1) CN1322136A (fr)
AP (1) AP2001002113A0 (fr)
AU (1) AU766095B2 (fr)
BR (1) BR9816047A (fr)
CA (1) CA2345378A1 (fr)
HK (1) HK1040617A1 (fr)
IL (1) IL142120A0 (fr)
WO (1) WO2000016794A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE314084T1 (de) 2000-10-31 2006-01-15 Pharma Mar Sa Kahalalid f formulierung
WO2005103255A1 (fr) * 2004-03-25 2005-11-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recepteur formylpeptide (fpr) utilise en tant que cible pour une therapie anti-gliome malin
WO2019232227A1 (fr) 2018-05-30 2019-12-05 Zap Surgical Systems, Inc. Neuromodlation radiochirurgicale proche de structures critiques
CN118286388A (zh) * 2024-04-12 2024-07-05 中国人民解放军军事科学院军事医学研究院 环孢素在治疗肠道放射损伤中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE520730C2 (sv) * 1995-01-20 2003-08-19 Eskil Elmer Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel
JP3089350B2 (ja) * 1995-11-20 2000-09-18 ギルフォード ファーマシューティカルズ インコーポレイテッド シクロフィリンロタマーゼ活性の阻害剤

Also Published As

Publication number Publication date
WO2000016794A1 (fr) 2000-03-30
HK1040617A1 (zh) 2002-06-21
IL142120A0 (en) 2002-03-10
AU9508198A (en) 2000-04-10
AP2001002113A0 (en) 2001-06-30
EP1115412A4 (fr) 2004-12-15
BR9816047A (pt) 2003-01-07
JP2002526453A (ja) 2002-08-20
AU766095B2 (en) 2003-10-09
CN1322136A (zh) 2001-11-14
EP1115412A1 (fr) 2001-07-18

Similar Documents

Publication Publication Date Title
AP734A (en) Method of treating a human with nervous insult with cyclosporin.
Kaku et al. Superselective intra-arterial infusion of papaverine for the treatment of cerebral vasospasm after subarachnoid hemorrhage
Abigerges et al. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea
Clayton et al. Does growth hormone cause relapse of brain tumours?
Borlongan et al. Bradykinin receptor agonist facilitates low-dose cyclosporine-A protection against 6-hydroxydopamine neurotoxicity
US20040147433A1 (en) Neuroimmunophilins for selective neuronal radioprotection
Honey et al. Human neural graft function in rats treated with anti-interleukin II receptor antibody
AU766095B2 (en) Neuroimmunophilins for selective neuronal radioprotection
Mishra et al. Intravesical tacrolimus in treatment of intractable interstitial cystitis/bladder pain syndrome–A pilot study
EP3701956B1 (fr) Agent prophylactique et/ou thérapeutique contre la démence
JP2655694B2 (ja) 自己免疫起源の脱髄性疾患、特に多発性硬化症を処置するための医薬組成物
NZ510739A (en) Neuroimmunophilins for selective neuronal radioprotection
RU2222343C2 (ru) Нейроиммунофилины для селективной противолучевой защиты нейронов
MXPA01003029A (en) Neuroimmunophilins for selective neuronal radioprotection
Stancioiu et al. Post-stroke recovery of motor function with a new combination of medicines-A pilot study
EP1091750B1 (fr) Composition pharmaceutique cerebrospinale et vasculaire et procede de preparation de ladite composition
Clarke et al. Confusion and paranoia associated with oral tocainide
US3885030A (en) Medicine comprising lysine by-products
US7846901B2 (en) Method for inhibiting or treating intestinal damage caused by radiotherapy or chemotherapy comprising administering substance-P
SU1255134A1 (ru) Способ лечени болевого синдрома при инфаркте миокарда
Lee et al. High incidence of local venous reactions to esorubicin
Tripathi et al. Vincristine-Potent Mitotic Inhibitor
CN115957220A (zh) 硝酮嗪在制备治疗缺血性脑卒中药物中的应用
WO2024102696A1 (fr) Utilisations de liposomes multivésiculaires de bupivacaïne comme bloc du ganglion stellaire pour le traitement de troubles anxieux et de traumatismes crânio-cérébraux
Waxman Management of depression.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued